Jan A. Alfheim

Company: Oncoinvent
Job title: Chief Executive Officer
Seminars:
Phase 1 Development of Radspherin 2:45 pm
Radspherin®, is a new alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities Radspherin® has in animal models been shown to cause a reduction in tumour cell growth and a significant increased survivalRead more
day: Day 1 Track A